"Word of mouse": indigenous harm reduction and online consumerism of the synthetic compound methoxphenidine.
Marie Claire Van Hout, Evelyn Hearne
Journal of Psychoactive Drugs 2015 DOI: 10.1080/02791072.2014.974002 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Phenomenological analysis Peer reviewed |
|---|---|
| Population | Recreational drug users posting on public Internet fora |
| Keywords | Internet Mxp Methoxetamine Methoxphenidine Indigenous harm reduction |
| Key points | Methoxphenidine produces a dissociative and stimulant wave lasting days, with acute side-effects of hypertension and seizures and chronic effects of memory loss and limb numbness. |
Abstract
Methoxphenidine (MXP) was one of several NMDA antagonists marketed in 2013 to replace the recently controlled compound Methoxetamine (MXE). A steep rise in user interest was recorded, despite vendor cautioning of limited user feedback. The study presented a phenomenological analysis of MXP experiences amongst recreational drug users as posted on public Internet fora. Internet searches were carried out using specific key words; "methoxphenidine," "MXP" and in combination with "experience," "report," "forum," and "trip." Seven self-reported experiences and 28 thread discussions relating sole use of MXP were analyzed using the Empirical Phenomenological Psychological method. Five themes and 61 categories emerged. MXP is marketed as a legal replacement for MXE, diphenidine, and ketamine, with a dissociative and stimulant wave outcome often lasting for days. Harm reduction tactics, awareness of prior tolerance to dissociative and optimal settings for use are discussed. Acute side-effects relate to hypertension and seizures. Chronic long-term memory loss and limb numbness is reported. Sense of empowerment occurs in the afterglow experience. Internet drug fora fuel information exchange and informed consumerism of synthetic compounds, and offer viable mechanisms for pre- and post-purchase decision making and indigenous harm reduction. Continued surveillance of synthetic market entries and user trends is warranted.
Citations in the library
Cited by 13
- New psychoactive substances (NPS) and serotonin syndrome onset: A systematic review. Experimental Neurology May 1, 2021
- Test purchase, synthesis, and characterization of 2‐methoxydiphenidine (MXP) and differentiation from its meta‐ and para‐substituted isomers Drug Testing and Analysis April 15, 2015
- An approach to the new psychoactive drugs phenomenon Salud Mental April 3, 2017
- New insights into methoxetamine mechanisms of action: Focus on serotonergic 5-HT2 receptors in pharmacological and behavioral effects in the rat. Experimental Neurology November 1, 2021
- The acute effects of methoxphenidine on behaviour and pharmacokinetics profile in animal model. Progress in Neuro-Psychopharmacology and Biological Psychiatry March 20, 2025
and 8 more in the library
Cites 21
- Recreational MDMA use in Sydney: a profile of ‘Ecstasy’ users and their experiences with the drug British Journal of Addiction August 1, 1992
- Clinical toxicology of newer recreational drugs Clinical Toxicology October 1, 2011
- The Experimental Use of Psychedelic (LSD) Psychotherapy JAMA June 15, 1970
- 'Surfing the Silk Road': a study of users' experiences. International Journal of Drug Policy November 1, 2013
- "Legal highs" on the net-Evaluation of UK-based Websites, products and product information. Forensic Science International March 20, 2011
and 16 more in the library